Lithium, a primary medication for treatment of bipolar disorder, promotes degradation of NR1D1 through inhibition of GSK3, whereas GSK3 phosphorylation stabilizes NR1D1 [45]. This evidence concerns the gene NR1D1 and bipolar disorder.